explore -WSS

explore

author：Wikipedia 2025-09-29 16:34:30 - browse：3

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Children’s Hospital revives plan for pedestrian bridge

WSS

CDC advisory group OKs chikungunya vaccine

Neuroscience renaissance leads to new crop of psychiatric drugs

Study fuels hope CAR

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Changes to biosimilar regulatory framework must prioritize patients

Change Healthcare cyberattack shows risk of industry consolidation

Wikipedia

explore

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Hearing on Medicare drug price negotiation gets unusually heated

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Using force crossed my mind when examining a defiant young patient

Drug repurposing or repositioning? The language matters

Why are Kaiser Permanente staff considering a strike?

Trump demands the U.S. pay no more for drugs than other countries … again

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

explore

Changes to biosimilar regulatory framework must prioritize patients

Biotech stock slump in 2023: awaiting the turnaround

Biotech stock slump in 2023: awaiting the turnaround

CDC panel: People 65 and older should get a Covid spring booster shot

Medicare isn't yet testing food as medicine

Intarcia’s device

entertainment

focus

knowledge

focus